Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Zhiyue Rao, Jian Zhang et al.|Nature Medicine|2025Cited by 30
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.Zhichao Jiang, Aiping Zhou, Wei Deng et al.|Journal of Clinical Oncology|2022Cited by 0